新诺威：拟与石药集团中奇制药共同投资设立合资公司，聚焦于GLP-1靶点等相关产品

Core Viewpoint - The company plans to establish a joint venture with Zhongqi Pharmaceutical Technology Co., Ltd. with a total investment of 450 million RMB, focusing on the development and commercialization of innovative metabolic drugs targeting GLP-1 [1] Group 1: Joint Venture Details - The company will contribute 157 million RMB, representing 35% of the registered capital [1] - Zhongqi Pharmaceutical will invest 292 million RMB, holding 65% of the registered capital [1] - The joint venture will primarily focus on the research, industrialization, and commercialization of innovative metabolic drugs [1] Group 2: Transaction Classification - This transaction is classified as a related party transaction and does not constitute a major asset reorganization [1]